Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Depreciation & Amortization (CF) (2024 - 2025)

Indivior Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 2 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $2.0 million for Q4 2025, down 60.0% from a year ago — trailing twelve months through Dec 2025 was $12.0 million (down 33.33% YoY), and the annual figure for FY2025 was $10.0 million, down 37.5%.
  • Depreciation & Amortization (CF) for Q4 2025 was $2.0 million at Indivior Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for INDV hit a ceiling of $5.0 million in Q1 2024 and a floor of $2.0 million in Q3 2025.